Forum
  Questionnaire on the Medical Professionals’ Assessment of the Description Order of Package Insert Contents and Appreciation of Conditions for Drug Approval
    Mariko IWASE, et al. 33

Report
  Report of Trainee of the Foreign Clinical Pharmacology Training Program: No. 1
    Atsushi SAKURABA 41
  Report of Trainee of the Foreign Clinical Pharmacology Training Program: No. 2
    Takahiro OHARA 45

Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics
  Contents 49
  Symposium 16 “Dose Difference in Multi-National Clinical Trial and Its Evidence” 53
  Symposium 17 “Oral Bacteria-Related Systemic Diseases: Up-to-Date” 63
  Symposium 20 “Scrutinizing the Current Educational Contents for Clinical Pharmacology in the Model Core-Curriculums for Medical Doctors and Pharmacists” 73
  Symposium 22 “How to Boost Early-Phase Exploratory Trials (FIM & POC Studies) in Japan” 83
  Symposium 24 “Challenges in New Drug Development” 93
  Symposium 25 “Current Status of Chronomedicine” 103

Minutes of JSCPT Administrative Meetings 41E

Drug Information 67E

Information for Authors 71E

Announcements 73E
Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

December 1–3, 2010 (Kyoto)
President: Ken-ichi INUI (Emeritus Professor, Kyoto University/President, Kyoto Pharmaceutical University)

Symposium 16 “Dose Difference in Multi-National Clinical Trial and Its Evidence”
Summary
S16–1 Difference on Clinical Dose between Three Areas and Pharmacokinetics of Drugs
Kanji TAKADA, et al. 53
S16–2 Ethnic Factors in Drug Dosing and Evidence-Based Medicine in Global Clinical Trials
Eri OKUKDA, et al. 55
S16–3 International Differences in Approved and Used Dosing for Drugs
Tetsuya NAKAMURA 57
S16–4 Dose Selection in Global Clinical Trials --From the Reviewer’s Viewpoint--
Masahiro NAGAI 59
Kaori SHINAGAWA 61

Symposium 17 “Oral Bacteria-Related Systemic Diseases : Up-to-Date”
Summary
S17–1 Periodontal Diseases and 4 Systemic Diseases
Kazu UMEMURA, et al. 63
S17–2 Role of Oral Bacteria as a Risk Factor for NASH
Atsuo AMANO, et al. 65
S17–3 Discovery and Clarification of the Stroke Induced Oral Bacteria
Koichiro WADA, et al. 67
S17–4 A Possible New Risk Factor for Cerebral Stroke, a Dental Caries Pathogen with Collagen-Binding Protein and Inhibitory Activity of Platelet Aggregation
Kazuya Hokamura, et al. 69
Tokutaro TANAKA, et al. 71

Symposium 20 “Scrutinizing the Current Educational Contents for Clinical Pharmacology in the Model Core-Curriculums for Medical Doctors and Pharmacists”
Summary
S20–1 Current Status and Future of Medical Education about Drug Therapy
Hirotoshi ECHIZEN, et al. 73
S20–2 Education of Individualized Drug Therapy: From School of Pharmacy
Akio FUJIMURA 75
S20–3 The Education of Pharmaceutical Development in Medical Faculties
Takashi SUZUKI 77
Kyoichi OHASHI 79
S20–4 Make an Inspection of Clinical Pharmacology in the “Model Core Curriculum for Pharmaceutical Education”
Makoto WATANABE 81

Symposium 22 “How to Boost Early-Phase Exploratory Trials (FIM & POC Studies) in Japan”
S22–1 Summary
Ryuichi KATO, et al. 83
S22–2 Measures for Promoting Early-Stage Exploratory Clinical Studies and Preventing Japanese Clinical Trials’ Hollowing Out --From the View Point of Pharma Industries--
Osamu INAGAKI 85
S22–3 How to Boost Early-Phase Exploratory Trials(FIM & POC Studies) in Japan --From Foreign-Based Pharma Industry Perspective--
Masaru IWASAKI 87
S22–4 Role of Academic Institutions to Encourage Early Phase Exploratory Clinical Trials
Hiroshi WATANABE 89
S22–5 From the Viewpoint of Regulatory Science
Masanobu YAMADA 91

Symposium 24 “Challenges in New Drug Development”
Summary
S24–1 Current Project to Promote Development of Drugs of Unmet Medical Needs in Japan
Satoshi TOYOSHIMA, et al. 93
Kazuishi SEKINO 95
S24–2 Global Clinical Trials : Current Situation of New Drug Review and Clinical Trial Consultation Meetings in PMDA
Yuki ANDO 97
S24–3 Current Situation of Research Project in China-Japan-Korea Tripartite Cooperation
Yoshiaki UYAMA 99
S24–4 Perspective of Benefit Risk Evaluation in Post-Marketing
Junko SATO 101
Symposium 25 “Current Status of Chronomedicine”

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>S25-1</td>
<td>Circadian Clock System and Chronotherapy</td>
<td>Hitoshi OKAMURA</td>
<td>103</td>
</tr>
<tr>
<td>S25-2</td>
<td>Development of a Predict Tool for Drug-Induced Psychiatric Diseases by Applying the Biological Clock System</td>
<td>Kentarou USHIJIMA, et al.</td>
<td>105</td>
</tr>
<tr>
<td>S25-3</td>
<td>Circadian Rhythm and Cardiovascular Disease</td>
<td>Kazuomi KARIO</td>
<td>107</td>
</tr>
<tr>
<td>S25-4</td>
<td>Chronotherapy and Circadian Rhythm of Rheumatoid Arthritis</td>
<td>Hideto TO</td>
<td>109</td>
</tr>
</tbody>
</table>